EsoBiotec

Active

Public limited companyfounded 20205 yrs activeRue André Dumont 5, 1435 Mont-Saint-Guibert, BelgiumKBO/BCE: BE 0756.885.159

Summary

EsoBiotec has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €12.4m and a net result of €7.7m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 70% of 193 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Risk analysis Watch Report Compare

EsoBiotecActiveChecked score 81/100

Risk analysis Report Compare

Checked score

Score 2025

81 / 100

Excellent

Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability100▲+100

Solvency100▲+40

Growth78▲+46

Track record94

Bankruptcy probability, 12 months

0.5% Very low

0%0.5%1.5%4%10%≥ 25%

Credit up to €1,000,000 at 30 days acceptable

Liquidity ample (current ratio 4.07 against 1.76 in 2024; short-term debt: 24.6% and cash: 0.7% of total assets), and 24.7% of the assets are financed with debt.

Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Seven signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

75.3%

Return on assets

46.9%

Age of the figures

9 mo

Lower-failure-rate sector

In this sector companies fail less often than the Belgian average.

Gazette · bankruptcies per sector, NACE 72

Relative position

BE, all sectors

reference

Scientific research and development (NACE 72)

about 30% fewer bankruptcies

← fewer bankruptcies more bankruptcies →

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Growing equity

Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.

NBB · annual accounts 2025

Equity per financial year

2122232425

2021 to 2025 · latest year €12.4m

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.

NBB · 5 filings

Deviation from the deadline

2025

24 d early

2024

23 d early

2023

34 d early

2022

32 d early

2021

26 d early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 5 accounts on average 28 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

27-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

History

On 22 October 2020, EsoBiotec was incorporated by two natural persons, with a starting capital of EUR 2,500.¹² The registered office moved to Louvain-la-Neuve in 2020, to Charleroi in 2021 and to Mont-Saint-Guibert in 2022.³⁴⁵ The capital was increased 7 times between 2020 and 2025, most recently to EUR 15 million.⁶⁷⁸ Of the 7 current board members, Jean-Pierre LATERE has served longest, since 2021.⁹ Total assets went from EUR 4.7 million in 2021 to EUR 17 million in 2025 and headcount from 3.2 to 9.4 full-time equivalents.¹⁰

Go further with this company

How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema

In the rankings #4 company by equity in Walloon Brabant, Research and development sector #6 company by total assets in Walloon Brabant, Research and development sector #10 employer in Walloon Brabant, Research and development sector

Turnover

Not included in this filing

EBIT margin

Not included in this filing

Net result

€7.7m

2024 · -€6.9m

Working capital

€12.4m▲ 771%

2024 · €1.4m

Trend over the years

Chart Table

Click a name to add, emphasise or remove a line.

Every figure with its change against the fiscal year before

favourable unfavourable

Line20212022202320242025

Operating result-€196,295--€1.1m▼ 441%-€2.7m▼ 158%-€7.2m▼ 162%€11.1m

Net result-€198,317--€1.0m▼ 406%-€2.7m▼ 167%-€6.9m▼ 157%€7.7m

Equity€2.3m-€5.1m▲ 119%€2.4m▼ 52.9%€1.5m▼ 36.8%€12.4m▲ 726%

Total assets€4.7m-€7.3m▲ 53.8%€6.5m▼ 10.7%€4.3m▼ 34.0%€16.5m▲ 283%

Debt€2.4m-€2.2m▼ 8.2%€4.1m▲ 84.9%€2.8m▼ 32.4%€4.1m▲ 45.5%

Working capital€3.8m-€4.8m▲ 27.3%€4.8m▼ 1.4%€1.4m▼ 70.1%€12.4m▲ 771%

Staff (FTE)3.2-7▲ 119%9.6▲ 37.1%10.6▲ 10.4%9.4▼ 11.3%

Why a figure moved sharply

2025 Equity +726%, Total assets +283% on 2024. Cause not known from the registers.
2024 Net result -157% on 2023. The accounts now follow the full schema, last year the micro schema.
2023 Net result -167%, Equity -53% on 2022. Cause not known from the registers.
2022 Net result -406% on 2021. Cause not known from the registers.
2022 Equity +119%, Total assets +54% on 2021. Capital increase of €3,750,810 (Official Gazette 16-06-2022).

Result per fiscal year

Operating resultNet result

The operating result returns to profit in 2025: €11.1m after a loss of €7.2m in 2024, the highest result in the available series.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €16.5m

100.0%

Fixed assets €501 ▼ 99.9%

Current assets €16.5m ▲ 397%

Equity and liabilities €16.5m

75.3%

24.7%

Equity €12.4m ▲ 726%

Debt €4.1m ▲ 45.5%

Debt's share of the balance-sheet total falls from 65.0% to 24.7%. Equity and debt are higher.

Key figures and ratios

2025 value · change against 2024

EBITDA

€18.0m▲

2024 · -€1.8m

Cash flow

€14.7m▲

2024 · -€1.5m

Current ratio

4.07▲

2024 · 1.76

Debt to equity

0.33▼

2024 · 1.86

ROE

62.3%▲

2024 · -457.4%

ROA

46.9%▲

2024 · -160.0%

Interest coverage

50.29▲

2024 · -57.04

Debt ≤ 1 year

€4.0m▲

2024 · €1.9m

Income taxes

€4.1m▲

2024 · -€268,289

Staff costs

€2.6m▲

2024 · €1.0m

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 26,964 companies that looked in July 2024 the way this one looks now, 1.5% went bankrupt within 24 months and 95% are still going.

Micro
5 to 10 years old
solvency 30% or more
a profit of 5% of the balance sheet or more

1.5% went bankrupt

3.4% stopped otherwise

95% still going

A further 0.3% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.4%
3	0.5%	0.5%
4	0.6%	0.7%
5	0.8%	0.9%
6	1.2%	1.3%
7	1.5%	1.6%
8	1.7%	1.7%
9	2.7%	2.8%
10	5.3%	5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 26,964 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts

OverviewIncome statement Balance sheet Cash flow

Filed annual accounts As filed with the NBB · 2025 against 2024 · 50 lines

Balance sheet Code20242025

Assets

Total assets20/58€4.3m€16.5m▲

Fixed assets21/28€980,799€501▼

Tangible fixed assets22/27€979,735-

Plant, machinery and equipment23€209,454-

Furniture and vehicles24€319,205-

Leasing and similar rights25€451,076-

Financial fixed assets28€1,064€501▼

Current assets29/58€3.3m€16.5m▲

Amounts receivable within one year40/41€547,837€16.4m▲

Trade receivables40€32,010-

Other amounts receivable41€515,827€16.4m▲

Current investments50/53€1.4m-

Cash at bank and in hand54/58€1.3m€113,183▼

Deferred charges and accrued income490/1€51,383-

Equity and liabilities

Total equity and liabilities10/49€4.3m€16.5m▲

Equity10/15€1.5m€12.4m▲

Contributions10/11€12.3m€15.4m▲

Capital10€12.3m€15.4m▲

Issued capital100€12.3m€15.4m▲

Profit (loss) carried forward14-€10.7m-€3.0m▲

Amounts payable17/49€2.8m€4.1m▲

Amounts payable after more than one year17€905,201-

Financial debts170/4€905,201-

Amounts payable within one year42/48€1.9m€4.0m▲

Current portion of amounts payable after more than one year42€231,943-

Trade debts44€1.1m€398,138▼

Suppliers440/4€1.1m€398,138▼

Taxes, remuneration and social security45€192,392€3.7m▲

Taxes450/3€42,532€3.6m▲

Remuneration and social security454/9€149,860€1,189▼

Other amounts payable47/48€377,911-

Accrued charges and deferred income492/3-€18,220

Income statement Code20242025

Non-recurring operating income76A-€42.6m

Remuneration, social security and pensions62€1.0m€2.6m▲

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€5.4m€6.9m▲

Other operating charges640/8-€104,100

Non-recurring operating charges66A-€6.0m

Gross operating margin9900-€761,751€26.8m▲

Operating profit (loss)9901-€7.2m€11.1m▲

Financial income75/76B€54,116€1.1m▲

Recurring financial income75€54,116€1.1m▲

Financial charges65/66B€31,202€358,254▲

Recurring financial charges65€31,202€358,254▲

Profit (loss) for the period before taxes9903-€7.1m€11.8m▲

Income taxes67/77-€268,289€4.1m▲

Profit (loss) for the period9904-€6.9m€7.7m▲

Profit (loss) for the period to be appropriated9905-€6.9m€7.7m▲

Appropriation of the result

Profit (loss) to be appropriated9906-€10.7m-€3.0m▲

Profit (loss) brought forward from the previous period14P-€3.9m-€10.7m▼

Social balance

Average headcount (FTE)908710.69.4▼

The notes to these accounts (15 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line	2021	2022	2023	2024	2025	Change
Non-recurring operating income76A	-	-	-	-	€42.6m	-
Remuneration, social security and pensions62	€262,827	€697,557	€892,857	€1.0m	€2.6m	▲ 157%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630	€15,800	€2.5m	€1.8m	€5.4m	€6.9m	▲ 28.7%
Other operating charges640/8	-	-	-	-	€104,100	-
Non-recurring operating charges66A	-	-	€567,027	-	€6.0m	-
Gross operating margin9900	€82,332	€2.2m	€483,654	-€761,751	€26.8m	▲ 3,615%
Operating profit (loss)9901	-€196,295	-€1.1m	-€2.7m	-€7.2m	€11.1m	▲ 255%
Financial income75/76B	€22	€3	€27,873	€54,116	€1.1m	▲ 1,894%
Recurring financial income75	€22	€3	€27,873	€54,116	€1.1m	▲ 1,894%
Financial charges65/66B	€2,045	€22,687	€37,780	€31,202	€358,254	▲ 1,048%
Recurring financial charges65	€2,045	€22,687	€37,780	€31,202	€358,254	▲ 1,048%
Profit (loss) for the period before taxes9903	-€198,317	-€1.1m	-€2.7m	-€7.1m	€11.8m	▲ 265%
Income taxes67/77	-	-€80,792	-€72,294	-€268,289	€4.1m	▲ 1,617%
Profit (loss) for the period9904	-€198,317	-€1.0m	-€2.7m	-€6.9m	€7.7m	▲ 212%
Profit (loss) for the period to be appropriated9905	-€198,317	-€1.0m	-€2.7m	-€6.9m	€7.7m	▲ 212%

Line	2021	2022	2023	2024	2025	Change
Assets
Total assets20/58	€4.7m	€7.3m	€6.5m	€4.3m	€16.5m	▲ 283%
Fixed assets21/28	€481,483	€1.9m	€1.1m	€980,799	€501	▼ 99.9%
Intangible fixed assets21	€449,509	€682,638	-	-	-	-
Tangible fixed assets22/27	€31,116	€1.2m	€1.1m	€979,735	-	-
Plant, machinery and equipment23	-	€240,779	€219,285	€209,454	-	-
Furniture and vehicles24	€31,116	€993,247	€369,468	€319,205	-	-
Leasing and similar rights25	-	-	€508,579	€451,076	-	-
Financial fixed assets28	€858	€1,284	€1,064	€1,064	€501	▼ 52.9%
Current assets29/58	€4.3m	€5.4m	€5.4m	€3.3m	€16.5m	▲ 397%
Amounts receivable within one year40/41	€1.1m	€1.2m	€1.5m	€547,837	€16.4m	▲ 2,888%
Trade receivables40	€12,921	€10,070	€21,791	€32,010	-	-
Other amounts receivable41	€1.1m	€1.2m	€1.4m	€515,827	€16.4m	▲ 3,073%
Current investments50/53	-	-	€2.5m	€1.4m	-	-
Cash at bank and in hand54/58	€3.2m	€4.1m	€1.4m	€1.3m	€113,183	▼ 91.3%
Deferred charges and accrued income490/1	€3,156	€5,123	€45,914	€51,383	-	-
Equity and liabilities
Total equity and liabilities10/49	€4.7m	€7.3m	€6.5m	€4.3m	€16.5m	▲ 283%
Equity10/15	€2.3m	€5.1m	€2.4m	€1.5m	€12.4m	▲ 726%
Contributions10/11	€2.5m	€6.3m	€6.3m	€12.3m	€15.4m	▲ 25.9%
Capital10	€2.5m	€6.3m	€6.3m	€12.3m	€15.4m	▲ 25.9%
Issued capital100	€2.5m	€6.3m	€6.3m	€12.3m	€15.4m	▲ 25.9%
Profit (loss) carried forward14	-€198,317	-€1.2m	-€3.9m	-€10.7m	-€3.0m	▲ 71.9%
Amounts payable17/49	€2.4m	€2.2m	€4.1m	€2.8m	€4.1m	▲ 45.5%
Amounts payable after more than one year17	-	€615,686	€2.5m	€905,201	-	-
Financial debts170/4	-	€615,686	€2.5m	€905,201	-	-
Amounts payable within one year42/48	€459,553	€536,801	€645,837	€1.9m	€4.0m	▲ 114%
Current portion of amounts payable after more than one year42	-	€176,435	€220,770	€231,943	-	-
Trade debts44	€459,458	€305,305	€358,116	€1.1m	€398,138	▼ 63.4%
Suppliers440/4	€459,458	€305,305	€358,116	€1.1m	€398,138	▼ 63.4%
Taxes, remuneration and social security45	-	€54,751	€66,856	€192,392	€3.7m	▲ 1,797%
Taxes450/3	-	€62	-	€42,532	€3.6m	▲ 8,479%
Remuneration and social security454/9	-	€54,689	€66,856	€149,860	€1,189	▼ 99.2%
Other amounts payable47/48	€95	€310	€95	€377,911	-	-
Accrued charges and deferred income492/3	€2.0m	€1.1m	€997,809	-	€18,220	-

Line	2021	2022	2023	2024	2025	Change
Profit (loss) for the period9904	-€198,317	-€1.0m	-€2.7m	-€6.9m	€7.7m	▲ 212%
+ Depreciation and write-downs630	€15,800	€2.5m	€1.8m	€5.4m	€6.9m	▲ 28.7%
Operating cash flow (approximation)	-€182,518	€1.5m	-€913,844	-€1.5m	€14.7m	▲ 1,085%
Investment in fixed assets (approximation)	-	-€4.0m	-€939,838	-€5.3m	-€6.0m	▼ 13.0%
Change in cash	-	€964,648	-€2.7m	-€95,822	-€1.2m	▼ 1,145%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

All 28Financial 5Gazette 18Filings 5

Next filing, fiscal year 2026, expected by 31-07-2027

2026

27-07

State Gazette act Appointment: Philippe Parone (director)

2 facts ▸

General meeting, 07-07-2026
Director appointment, Philippe Parone (director)

15-07

State Gazette act Resignations: KNCL SRL (daily management delegate) and Jean-Pierre Latere Dwan'Isa (director)

3 facts ▸

Board meeting, 22-06-2026
Director resignation, KNCL SRL (daily management delegate)
Director resignation, Jean-Pierre Latere Dwan'Isa (director)

07-07

NBB filing Annual accounts filed

fiscal year 2025 · full schema

2025

31-12

Financial Back to profitnet €7.7m

Net result €7.7m after 4 loss-making years.

31-12

Financial Liquidity doublescurrent ratio 4.07

Current ratio from 1.76 to 4.07.

31-12

Financial Equity above €10mEq €12.4m ▲726%

Equity rises from €1.5m to €12.4m.

27-10

State Gazette act Resignations: FONDS DE CAPITAL A RISQUE 2020 SA, Michel Briejer and 3 others

Appointments: Carsten Linnemann (director) and Angela Thompson (director) · Permanent representative: Héléna Pozios9 facts ▸

General meeting, 19-05-2025
Director resignation, FONDS DE CAPITAL A RISQUE 2020 SA (director)
Director resignation, Michel Briejer (director)
Director resignation, Paul Rennert (director)
Director resignation, Laura Rodriguez Gallego (director)
Director resignation, Erica Whittaker (director)
Director appointment, Carsten Linnemann (director)
Director appointment, Angela Thompson (director)
Permanent representative, Héléna Pozios

25-07

State Gazette act Reappointment: Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises BV/SRL (statutory auditor)

Appointment: KPMG Bedrijfsrevisoren BV (statutory auditor) · Auditor removal · Power of attorney6 facts ▸

General meeting, 09-07-2025
Auditor reappointment, Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises BV/SRL (statutory auditor)
Auditor removal, commissaire, Révocation du mandat
Auditor appointment, KPMG Bedrijfsrevisoren BV (statutory auditor)
Power of attorney, Harvest Avocats
Corporate acquisition, Acquisition of the company by AstraZeneca; the Astra Zeneca group decided to appoint KPMG to centralize external audit with one international network

08-07

NBB filing Annual accounts filed

fiscal year 2024 · full schema

28-05

State Gazette act Statutes amendment

Capital · Share concentration · Esop rights cancellation5 facts ▸

General meeting, 19-05-2025
Statutes amendment
Capital, €15.432.208,13
Share concentration, All shares held by a single shareholder, effective 2025-05-19
Esop rights cancellation, All unassigned ESOP subscription rights held by the company can no longer be exercised and/or have been cancelled, effective 2025-05-19; no subscription rights…

23-05

State Gazette act Capital & shares · Statutes amendment

Capital increase · Bank account · Capital5 facts ▸

Capital increase, €1.179.246,6
Bank account, CBC Banque SA, BE71 7320 5654 3169
Capital, €15.432.208,13
Statutes amendment
Power of attorney

26-02

State Gazette act Capital & shares · Statutes amendment

Capital increase · Share issue · Bank account9 facts ▸

Capital increase, €1.999.961,19
Share issue, actions préférentielles avec droit de vote, 158683
Bank account, CBC Banque SA
Capital, €14.252.961,53
Statutes amendment
Subscription period, 31-03-2025, 20-08-2024
Share payment, 100,00%, 1.999.961,19 EUR
Share nominal value, sans mention de valeur nominale
Share classes

Show earlier events

2024

31-12

Financial Weakest financial yearnet -€6.9m

Net result drops to -€6.9m, the lowest in the series; recovery starts the following year.

29-08

State Gazette act Reappointments: Jean-Pierre LATERE, Michel BRIEJER and 3 others

Appointment: Laura RODRIGUEZ GALLEGO (director) · Capital increase · Bank account23 facts ▸

General meeting, 20-08-2024
Capital increase, €2.000.000
Capital increase, €3.999.960,19
Bank account, compte spécial au nom de la Société, auprès de CBC Banque SA
Capital, €12.253.000,34
Share issue, droits de souscription anti-dilutifs, 12
Share issue, droits de souscription ESOP, 70482
Director reappointment, Jean-Pierre LATERE (director)
Director reappointment, Michel BRIEJER (director)
Director reappointment, FONDS CAPITAL A RISQUE 2020 (director)
Director reappointment, Erica WHITTAKER (director)
Director reappointment, Paul RENNERT (director)
+11 further facts in this act

27-06

NBB filing Annual accounts filed

fiscal year 2023 · micro schema

2023

29-06

NBB filing Annual accounts filed

fiscal year 2022 · micro schema

2022

31-12

Financial Equity above €5mEq €5.1m ▲119%

Equity rises from €2.3m to €5.1m.

29-11

State Gazette act Registered office

Registered-office move2 facts ▸

Board meeting, 12-11-2022
Registered-office move, 5 rue André Dumont, 1435 Mont-Saint-Guibert

19-10

State Gazette act Resignation: Emmanuel Lacroix (director)

Appointment: Erica Whittaker (director)3 facts ▸

General meeting, 29-09-2022
Director resignation, Emmanuel Lacroix (director)
Director appointment, Erica Whittaker (director)

05-07

NBB filing Annual accounts filed

fiscal year 2021 · micro schema

16-06

State Gazette act Capital & shares · Statutes amendment

Capital increase · Capital · Bank account8 facts ▸

General meeting, 15-12-2021
Capital increase, €3.750.810,23
Capital, €6.253.040,15
Bank account, CBC Banque
Capital increase
Share classes, Actions Ordinaires avec droit de vote, Actions Ordinaires sans droit de vote, Actions Préférentielles avec droit de vote
Capital increase
Bank account, CBC Banque, 09-06-2022

18-05

State Gazette act Capital & shares · Statutes amendment · Miscellaneous

Capital · Share issue · Capital increase10 facts ▸

General meeting, 11-05-2022
Capital, €2.502.229,92
Share issue, stock split, 456200
Statutes amendment
Share issue, droits de souscription ESOP
Capital increase, €prix d'exercice des droits de souscription ESOP multiplié par le nombre de droits de souscription ESOP exercés
Share issue, subscription rights split, 57300
Share issue, subscription rights modification, 57300
Share class creation, émises suite à l'exercice de droits de souscription ESOP, Actions Ordinaires sans droit de vote
Pre emptive rights waiver, Renonciation au droit de souscription préférentielle

2021

24-12

State Gazette act Resignation: Héléna POZIOS (director)

Appointments: Fonds de Capital à Risque 2020 (director) and Emmanuel LACROIX (director) · Capital increase · Bank account10 facts ▸

General meeting, 15-12-2021
Capital increase, €749.909,97
Bank account, 15-12-2021
Capital increase
Capital, €2.502.229,92
Share issue, droits de souscription anti-dilutifs, 2
Director resignation, Héléna POZIOS (director)
Director appointment, Fonds de Capital à Risque 2020 (director)
Director appointment, Emmanuel LACROIX (director)
Capital increase, €prix d'exercice des droits de souscription anti-dilutifs multiplié par le nombre de droits de souscription anti-dilutifs exercés

27-10

State Gazette act Appointment: KNCL SRL (daily management delegate)

Registered-office move4 facts ▸

Board meeting, 31-08-2021
Director appointment, KNCL SRL (daily management delegate)
Board meeting, 22-09-2021
Registered-office move, 6041 Charleroi, Rue Adrienne Bolland 8

13-10

State Gazette act Resignation: KNCL (sole director)

Appointments: LATERE Jean-Pierre, RENNERT Paul and 2 others · Capital increase · Share issue15 facts ▸

General meeting, 31-08-2021
Capital increase, €1.499.819,95
Share issue, droits de souscription anti-dilutifs, 6
Share issue, droits de souscription ESOP, 573
Legal-form conversion, Société anonyme
Net-asset statement, 30-06-2021
Capital, €1.752.319,95
Director resignation, KNCL (sole director)
Director appointment, LATERE Jean-Pierre (director)
Director appointment, RENNERT Paul (director)
Director appointment, BRIEJER Michel (director)
Director appointment, POZIOS Héléna (director)
+3 further facts in this act

2020

16-12

State Gazette act Capital & shares

Capital increase · Share issue · Bank account6 facts ▸

General meeting, 12-11-2020
Capital increase, €250.000
Share issue, 277, 12-11-2020
Bank account, CBC, BE71 7320 5654 3169
Statutes amendment
Capital, €252.500

01-12

State Gazette act Registered office

Registered-office move · Power of attorney4 facts ▸

Board meeting, 17-11-2020
Registered-office move, Chemin du Cyclotron 6, 1348 Louvain-la-Neuve
Power of attorney, Laetitia De Smet
Power of attorney, Magali de Fooz

26-10

State Gazette act Incorporation

Appointment: KNCL (non-statutory director) · Permanent representative: LATERE DWAN'ISA Jean-Pierre · Founding capital6 facts ▸

Incorporation, 20-10-2020
Founding capital, €2.500
Bank account, BE71 7320 5654 3169
Director appointment, KNCL (non-statutory director)
Permanent representative, LATERE DWAN'ISA Jean-Pierre
Mandate compensation, KNCL

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

18 of 18 acts read

Directors · office · real estate

Directors

6 directors, 1 in day-to-day management, no change since 2026

Board 6

Jean-Pierre LATERE

Director · since 31-08-2021

Current

FONDS DE CAPITAL A RISQUE 2020

Director · since 15-12-2021 · Legal entity

Current

Angela Thompson

Director · since 19-05-2025

Current

Carsten Linnemann

Director · since 19-05-2025

Current

Philippe Parone

Director · since 07-07-2026

Current

FONDS CAPITAL A RISQUE 2020

Director · Legal entity

Current

Day-to-day management 1

KNCL SRL

Daily management delegate · since 01-09-2021 · Legal entity

Current

Statutory auditor 2

Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises

Statutory auditor · since 09-07-2025

Current

KPMG Réviseurs d'Entreprises

Statutory auditor · since 09-07-2025

Current

Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →

Location & real-estate footprint

Registered office, Mont-Saint-Guibert · 1 establishment unit since 2020

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue André Dumont 51435 Mont-Saint-Guibert

1 establishment unit

Rue André Dumont 5, 1435 Mont-Saint-Guibert

Manufacture of basic pharmaceutical products and pharmaceutical preparations

since 20202.309.360.657

Mandate history

19 people since 2020, 9 in office

All 19 In office 9 Ended 10

Board
Day-to-day management
Statutory auditor
began earlier

Mandates per person, with start and end dates
Name	Functions and periods
Jean-Pierre LATERE	Director, from 31-08-2021 to date
FONDS DE CAPITAL A RISQUE 2020	Director, from 15-12-2021 to date
FONDS CAPITAL A RISQUE 2020	Director, already before 29-08-2024 to date
Angela Thompson	Director, from 19-05-2025 to date
Carsten Linnemann	Director, from 19-05-2025 to date
Philippe Parone	Director, from 07-07-2026 to date
KNCL SRL	Daily management delegate, from 01-09-2021 to date
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises	Statutory auditor, from 09-07-2025 to date
KPMG Réviseurs d'Entreprises	Statutory auditor, from 09-07-2025 to date
KNCL	Non-statutory director, from 22-10-2020 ended, last mentioned 26-10-2020 Daily management delegate, until 06-07-2026
LATERE DWAN'ISA Jean-Pierre	Director, until 06-07-2026
Erica Whittaker	Director, from 05-08-2022 to 19-05-2025
FONDS DE CAPITAL A RISQUE 2020	Director, until 19-05-2025
Laura RODRIGUEZ GALLEGO	Director, from 20-08-2024 to 19-05-2025
Michel Briejer	Director, from 31-08-2021 to 19-05-2025
Paul Rennert	Director, from 31-08-2021 to 19-05-2025
Emmanuel Lacroix	Director, from 15-12-2021 to 05-08-2022
Héléna Pozios	Director, from 31-08-2021 to 15-12-2021
KNCL	Sole director, until 31-08-2021

Show all 19 people Show the first 12See the board, name and seat on a given date →

Articles of association

Purpose

Toutes activités liées à l'importation, l'exportation, l'achat, la vente, la distribution, la conception, le développement, la fabrication, la commercialisation de produits…

Full purpose

Toutes activités liées à l'importation, l'exportation, l'achat, la vente, la distribution, la conception, le développement, la fabrication, la commercialisation de produits naturels, biologiques, cosmétiques, pharmaceutiques, etc., ainsi que la recherche, le développement, la gestion de droits intellectuels, les services de santé, etc.

according to the deed of 28-05-2025

Structure & network

Owners and holdings

1 owner

Chain of control

Neogene TherapeuticsNL 100%
EsoBiotec

Highest known parent: Neogene Therapeutics (Netherlands). The sources do not say who stands above it.

Owners 1

Neogene TherapeuticsNLparent

Sourceown accounts 2025

100%

Stated earlier (1)

An older source named these owners; newer accounts no longer list them.

SOCIETE REGIONALE D'INVESTISSEMENT DE WALLONIE, EN ABREGE : S.R.I.W.

Sourceaccounts SOCIETE REGIONALE D'INVESTISSEMENT DE WALLONIE, EN ABREGE : S.R.I.W. 2022

13.16%

Holdings 0

The accounts to 31-12-2025 list no holdings, and no other source names one.

According to the 2025 annual accounts of EsoBiotec and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

7 current directors

Depth

The network starts from this company’s directors. Other companies they run appear here as nodes.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.

Capital and shareholders

Shareholders according to the acts

After the capital increase act of 13-10-2021 ↗

Thuja Capital Healthcare Fund III Coöperatief U.A. 595 shares
FONDS DE CAPITAL A RISQUE 2020 (BE 0667.964.566) 298 shares
Société Régionale d'Investissement de Wallonie (BE 0219.919.487) 297 shares

After the capital increase act of 16-12-2020 ↗

KNCL (BE 0645.689.309) 100 shares · 90,000 EUR
Mireille KABAMBA MWIKA 55 shares · 50,000 EUR
Origène NYANGUILE 28 shares · 25,000 EUR
Philippe PARONE 33 shares · 30,000 EUR
Natacha VAN HOEKEN 33 shares · 30,000 EUR
Zoor LUONO 28 shares · 25,000 EUR

At incorporation act of 26-10-2020 ↗

LATERE DWAN'ISA Jean-Pierre 1,250 shares (50%) · 1,250 EUR
KABAMBA NKONGOLO 1,250 shares (50%) · 1,250 EUR

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years

28-05-2025 Capital stated in the act · 15,432,208.13 EUR · 1,482,129 shares
23-05-2025 Capital increase of 1,179,246.60 EUR · to 15,432,208.13 EUR · 93,591 new shares
26-02-2025 Capital increase of 1,999,961.19 EUR · to 14,252,961.53 EUR · 158,683 new shares
29-08-2024 Capital increase of 2,000,000 EUR · to 8,253,040.15 EUR · 158,686 new shares
29-08-2024 Capital increase of 3,999,960.19 EUR · to 12,253,000.34 EUR · 317,369 new shares
29-08-2024 Capital increase of 1,999,961.19 EUR · to 14,252,961.53 EUR
16-06-2022 Capital increase of 3,750,810.23 EUR · to 6,253,040.15 EUR · 297,600 new shares · in cash
18-05-2022 Capital stated in the act · 2,502,229.92 EUR · 456,200 shares

Show 4 older capital entries

24-12-2021 Capital increase of 749,909.97 EUR · to 2,502,229.92 EUR · 595 new shares
13-10-2021 Capital increase of 1,499,819.95 EUR · 1,190 new shares
16-12-2020 Capital increase of 250,000 EUR · to 252,500 EUR · 277 new shares
26-10-2020 Incorporation · 2,500 EUR · 2,500 shares

Similar companies · same sector, comparable size

CROPLIFE INTERNATIONAL

BE 0407.599.740

Brussel · Eq €12.7m

INSTITUUT BORN-BUNGE VOOR WETENSCHAPPELIJK ONDERZOEK VZW

BE 0408.628.138

Antwerpen · Eq €12.1m

INTRESSA VASCULAR

BE 0462.587.258

Gembloux · Eq €11.8m

Life Sciences Research Partners

Hoegaarden · Eq €11.6m

Of 1,177 companies in sector 72109 we hold annual accounts for 714. 176 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification

Legal formPublic limited company

Founded22-10-2020

Fiscal year end31-12

Activities, NACEBEL 2025

72109Other research and development on natural sciences

E-invoicing

Reachable via Peppol

Peppol ID 0208:0756885159

Registered 30-12-2025

Scores and ratios are computed by Checked and are not a credit decision.